Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 28/01/2008

    Europeans believe biodiversity loss is a problem

    For 93 of Europeans preserving biodiversity is a moral obligation affecting current generations as stewards of nature. European citizens are also aware that their well-being and quality of life depend on biodiversity.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/europeans-believe-biodiversity-loss-is-a-problem
  • Article - 26/01/2008

    New prosthetic methods

    All movements - each grip and step - have their origin in the brain. Carsten Mehring and his group at the Bernstein Centre for Computational Neuroscience and the Institute for Biology I at the University of Freiburg plan to use brain signals for the control of prostheses or for the operation of computers.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-prosthetic-methods
  • Article - 25/01/2008

    Glycosylation pattern as potential target for intervention

    Tumours develop sophisticated strategies to escape the immune defence. One of these strategies is the modification of the cells sugar coat. Specific immune cell receptors bind to these sugars thereby preventing the tumour cell from being discovered by the immune system. Medics from the University of Tübingen are investigating the mechanisms involved and are looking for therapeutic targets.

    https://www.gesundheitsindustrie-bw.de/en/article/news/glycosylation-pattern-as-potential-target-for-intervention
  • Article - 25/01/2008 The pericellular coat around an adherent cartilage cell (chondrocyte), visualized by an exclusion assay. A halo of several micrometers in thickness around the cell cannot be penetrated by the dense population of surrounding probe objects (red blood cells)

    How do cells work? Glycoconjugate cell coat models provide new answers

    At the Max Planck Institute for Metal Research in Stuttgart researchers are developing model systems that imitate the sugar coats of living cells. They hope to gain new insights into the regulation of biological functions and develop the system into a platform for biosensoric applications.

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-do-cells-work-glycoconjugate-cell-coat-models-provide-new-answers
  • Article - 25/01/2008

    More than just 'empty' calories: polysaccharides in food

    Oligosaccharides and low-molecular polysaccharides are polymers made of different sugar units. Specialist companies such as Esslingen-based Anoxymer GmbH are focusing on plant sugar structures that have a therapeutic and preventive benefit.

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-than-just-empty-calories-polysaccharides-in-food
  • Article - 21/01/2008

    Research alliance between French and German researchers

    Scientists from Ulm and Paris have joined forces to develop new medications against malignant brain tumours. The two-year research project will focus on developing betulinic acid which is found in abundance in birch bark into a cancer drug.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-alliance-between-french-and-german-researchers
  • Press release - 21/01/2008

    Optical technologies - biophotonics and life sciences

    The BMBF has announced the guidelines for the new SMU innovative Optical Technologies funding programme.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/optical-technologies-biophotonics-and-life-sciences
  • Article - 21/01/2008

    Research project "Applied Pathogenomics"

    The deadline for the submission of preproposals is 29th February 2008.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-project-applied-pathogenomics
  • Article - 21/01/2008

    EU strengthens innovation potential of electronic health services

    The EU hopes to tap innovative markets through a Lead Markets Initiative LMI in which electronic health services eHealth were identified as an important market.

    https://www.gesundheitsindustrie-bw.de/en/article/news/eu-strengthens-innovation-potential-of-electronic-health-services
  • Press release - 21/01/2008

    Micro-biolytics GmbH - Top spectroscopy technology for the pharmaceutical industry

    Micro-biolytics GmbH now based in the Esslingen-based Life Science Centre develops and produces microsystems solutions for bioanalytical issues. With the support of networks micro-biolytics is hoping to considerably expand its activities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/micro-biolytics-gmbh-top-spectroscopy-technology-for-the-pharmaceutical-industry
  • Press release - 20/01/2008 Building of GATC Biotech AG in Konstanz

    LifeCodexx AG - Clarity within the genetic data jungle

    Constance based GATC Biotech founds the subsidiary company LifeCodexx AG. LifeCodexx is the first web-based information service for the storage and utilisation of biological and medical data from the analysis of genetic codes and protein codes in the EU.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/lifecodexx-ag-clarity-within-the-genetic-data-jungle
  • Press release - 20/01/2008 Computer generated model of the blood vessels of a human heart. The colors indicate a specific blood flow parameter.

    Genetic causes and therapy of cardiac insufficiency

    Since 2001 the Medical University Hospital in Heidelberg has coordinated the Cardiovascular Network within the framework of the National Genome Research Network NGFN which also involves nine other big German university hospitals.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/genetic-causes-and-therapy-of-cardiac-insufficiency
  • Article - 19/01/2008

    Zeiss continues fourth year of dynamic development

    Sales revenues of the Carl Zeiss Group rose by seven per cent to 2604 million. The growth posted for EbIT Earnings before Interest and Taxes increased by 26 per cent to 394 million. Zeiss AG is thus continuing the series of successes that has lasted for four years.

    https://www.gesundheitsindustrie-bw.de/en/article/news/zeiss-continues-fourth-year-of-dynamic-development
  • Press release - 19/01/2008

    New Microbial Genome-to-Array Service

    Partnering with Prognosys Biosciences febit offers a new Genome-to-Array Service. This Service gives scientists access to the latest technology and know-how in sequencing and microarrays even for DNA where no standard microarrays are available.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-microbial-genome-to-array-service
  • Article - 19/01/2008

    Aiming for a National Centre for Dementia Research

    The Rhine-Neckar metropolitan region is hoping to become a National Centre for Dementia Research. Professor Beyreuther director of the NAR at the University of Heidelberg is coordinating the application.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/aiming-for-a-national-centre-for-dementia-research
  • Article - 15/01/2008

    Female hearts fibrillate differently

    Gender-specific differences are currently not only a subject of debate for experts but have also raised broad media interest. However there are very few specific investigations that are able to provide a clear answer said Prof. Volker Kühlkamp chief physician in the Department of CardiologyElectrophysiology at the Lake Constance Heart Centre in ConstanceKreuzlingen and specialist in cardiac arrhythmia.

    https://www.gesundheitsindustrie-bw.de/en/article/news/female-hearts-fibrillate-differently
  • Press release - 15/01/2008

    ALVESCO® gains FDA approval for the U.S. market

    The Food and Drug Administration approved Nycomeds ALVESCO ciclesonide Inhalation Aerosol in the United States for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/alvesco-gains-fda-approval-for-the-u-s-market
  • Press release - 14/01/2008

    Prostate cancer: Improving the success of treatment

    Prostate cancer is the most frequent malignant tumour in men. Researchers from Freiburg and Bonn have succeeded in developing the basics for new therapies in particular for the treatment of advanced prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-improving-the-success-of-treatment
  • Press release - 14/01/2008

    Industrial healthcare degree courses in Tuttlingen

    New degree courses look set to complement Baden-Württembergs higher education landscape. The Council of Ministers took the decision to establish a Furtwangen University of Applied Sciences department in Tuttlingen.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/industrial-healthcare-degree-courses-in-tuttlingen
  • Article - 14/01/2008 Laying the foundation stone for the new building (from left to right): Dr. Christoph Gaissmaier, Dr. Jürgen Fritz (both on the managing board of TETEC AG), Prof. Drs. Michael Ungethüm, Dr. Harald Stallforth (both on the managing board of Aesculap AG & Co. KG).

    Tetec AG to erect new building in Reutlingen

    Tetec AG a leader in regenerative medicine is building a new facility in ReutlingenKusterdingen in which Aesculap AG is the only investor. This construction represents a major progress for the Medical technology and health TuttlingenNeckar-Alb top cluster.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tetec-ag-to-erect-new-building-in-reutlingen
  • Press release - 13/01/2008

    Thrombosis in the brain

    Researchers led by a scientist at the Department of Neurology at the University Hospital in Heidelberg has identified a new gene variant as a risk factor for cerebral venous thromboses. 16.7 per cent of patients with cerebral venous thrombosis had the new variant compared to only 5.5 per cent of the healthy population.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/thrombosis-in-the-brain
  • Article - 12/01/2008

    Peptide chips for improved cancer diagnostics

    Scientists at the German Cancer Research Centre DKFZ have now succeeded in generating peptides on a microchip - faster and thus cheaper than with previous methods.

    https://www.gesundheitsindustrie-bw.de/en/article/news/peptide-chips-for-improved-cancer-diagnostics
  • Press release - 10/01/2008

    Genetic Testing of IVF Embryos

    A new report by European Commission scientists gives a full picture of preimplantation genetic diagnosis PGD. Parents need better information on genetic testing of IVF embryos.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/genetic-testing-of-ivf-embryos
  • Press release - 08/01/2008

    How thoughts are generated

    What is a thought? First of all it is a firework of neuronal activity produced by the neurons which encode and transmit information as electrical impulses. However when we think or remember something there is not always an input from the environment.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-thoughts-are-generated
  • Article - 07/01/2008 Portrait of professor doctor Thomas Hirth

    Thomas Hirth becomes new director of the Fraunhofer IGB

    Prof. Dr. Thomas Hirth took over the management of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart. In 1992 he became a scientist at the Fraunhofer Institute for Chemical Technology ICT in Karlsruhe.

    https://www.gesundheitsindustrie-bw.de/en/article/news/thomas-hirth-becomes-new-director-of-the-fraunhofer-igb

Page 118 / 119

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 115
  • 116
  • 117
  • 118
  • 119
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search